102 related articles for article (PubMed ID: 7562399)
21. A fast capillary electrophoresis method for separation and quantification of modified nucleosides in urinary samples.
Jiang Y; Ma Y
Anal Chem; 2009 Aug; 81(15):6474-80. PubMed ID: 19552424
[TBL] [Abstract][Full Text] [Related]
22. [Expression of modified nucleoside, 1-methyladenosine in intraocular tumors and the retinas].
Takahashi R; Shiono T; Tamai M; Itoh K; Mizugaki M
Nippon Ganka Gakkai Zasshi; 1993 Jan; 97(1):43-9. PubMed ID: 8434538
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of the advantage of determination of urinary pseudouridine for the early detection of a malignant transformation process].
Senden D; Buchet JP; Lauwerys R
J Toxicol Clin Exp; 1990; 10(7-8):473-80. PubMed ID: 2135063
[TBL] [Abstract][Full Text] [Related]
24. [Application of urinary nucleosides in the diagnosis and surgical monitoring of colorectal cancer].
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Yu BM
Zhonghua Wai Ke Za Zhi; 2005 May; 43(9):564-8. PubMed ID: 15938925
[TBL] [Abstract][Full Text] [Related]
25. Preparation of a monoclonal antibody specific for 1-methyladenosine and its application for the detection of elevated levels of 1-methyladenosine in urines from cancer patients.
Itoh K; Mizugaki M; Ishida N
Jpn J Cancer Res; 1988 Oct; 79(10):1130-8. PubMed ID: 3143701
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of N2, N2-dimethylguanosine and pseudouridine as determined by radioimmunoassay for patients with malignancy.
Levine L; Waalkes TP; Stolbach L
J Natl Cancer Inst; 1975 Feb; 54(2):341-3. PubMed ID: 1117461
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of urinary and serum pseudouridine in diagnosis and monitoring of primary liver cancer.
Tu Z; Xu S; Wu M
Chin Med J (Engl); 1995 Mar; 108(3):204-8. PubMed ID: 7796629
[TBL] [Abstract][Full Text] [Related]
28. Urinary excretion of pseudouridine in patients with brain tumours.
Manjula S; Aroor AR; Raja A; Rao S; Rao A
Acta Oncol; 1993; 32(3):311-4. PubMed ID: 8323769
[TBL] [Abstract][Full Text] [Related]
29. Reference intervals for eight modified nucleosides in serum in a healthy population from Italy and the United States.
Pane F; Oriani G; Kuo KC; Gehrke CW; Salvatore F; Sacchetti L
Clin Chem; 1992 May; 38(5):671-7. PubMed ID: 1582018
[TBL] [Abstract][Full Text] [Related]
30. Pseudouridine as a novel biomarker in prostate cancer.
Stockert JA; Weil R; Yadav KK; Kyprianou N; Tewari AK
Urol Oncol; 2021 Jan; 39(1):63-71. PubMed ID: 32712138
[TBL] [Abstract][Full Text] [Related]
31. Blood plasma pseudouridine in patients with malignant proliferative diseases.
Motyl T; Traczyk Z; Cieśluk S; Daniewska-Michalska D; Kukulska W; Kałuzny Z; Podgurniak M; Orzechowski A; Debski B
Eur J Clin Chem Clin Biochem; 1993 Nov; 31(11):765-71. PubMed ID: 8305621
[TBL] [Abstract][Full Text] [Related]
32. Ascitic pseudouridine discriminates between hepatocarcinoma-derived ascites and cirrhotic ascites.
Castaldo G; Intrieri M; Calcagno G; Cimino L; Budillon G; Sacchetti L; Salvatore F
Clin Chem; 1996 Nov; 42(11):1843-6. PubMed ID: 8906086
[TBL] [Abstract][Full Text] [Related]
33. Serum pseudouridine as a biochemical marker in small cell lung cancer.
Tamura S; Fujioka H; Nakano T; Hada T; Higashino K
Cancer Res; 1987 Nov; 47(22):6138-41. PubMed ID: 2822241
[TBL] [Abstract][Full Text] [Related]
34. Breast cancer prognostic significance of some modified urinary nucleosides.
Sasco AJ; Rey F; Reynaud C; Bobin JY; Clavel M; Niveleau A
Cancer Lett; 1996 Nov; 108(2):157-62. PubMed ID: 8973589
[TBL] [Abstract][Full Text] [Related]
35. Analysis of urinary nucleosides as helper tumor markers in hepatocellular carcinoma diagnosis.
Jeng LB; Lo WY; Hsu WY; Lin WD; Lin CT; Lai CC; Tsai FJ
Rapid Commun Mass Spectrom; 2009 Jun; 23(11):1543-9. PubMed ID: 19399767
[TBL] [Abstract][Full Text] [Related]
36. Possible use of urinary modified RNA metabolites in the measurement of RNA turnover in the human body.
Sander G; Topp H; Wieland J; Heller-Schöch G; Schöch G
Hum Nutr Clin Nutr; 1986 Mar; 40(2):103-18. PubMed ID: 2420752
[TBL] [Abstract][Full Text] [Related]
37. Modified nucleosides in urine: selective removal and analysis.
Uziel M; Smith LH; Taylor SA
Clin Chem; 1976 Sep; 22(9):1451-5. PubMed ID: 954194
[TBL] [Abstract][Full Text] [Related]
38. The use of receiver operating characteristic (ROC) curves analysis in the evaluation of the diagnostic efficiency of serum pseudouridine as a tumor marker.
Savoia M; Pane F; Fortunato G; Salvatore F; Sacchetti L
Ital J Biochem; 1988; 37(2):119-27. PubMed ID: 3403212
[TBL] [Abstract][Full Text] [Related]
39. Determination of degradation rates of transfer and ribosomal ribonucleic acids in cultured rat hepatocytes by measuring N6-threoninocarbonyladenosine, dihydrouridine, and pseudouridine in medium using high-performance liquid chromatography.
Topp H; Dörrenhaus A; Bolt H; Schöch G; Föllmann W
Anal Biochem; 1997 Dec; 254(2):200-7. PubMed ID: 9417777
[TBL] [Abstract][Full Text] [Related]
40. Pseudouridine determination in blood serum as tumor marker.
Salvatore F; Russo T; Colonna A; Cimino L; Mazzacca G; Cimino F
Cancer Detect Prev; 1983; 6(6):531-6. PubMed ID: 6318996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
